A pioneering study out of Western Australia has shown that a longer acting intravitreal dexamethasone implant (DEX-implant) may lead to better outcomes in some Aboriginal patients with diabetic macular oedema (DMO) compared with the standard of care, anti-VEGF injections.
Read More
